(R)-salbutamol in the treatment of asthma and chronic obstructive airways disease

Bibliography

• Hartley D, Middlemiss D. Absolute configuration of the optical isomers of salbutamol. J Med Chem 1971;14:995-6
   PubMedGoogle Scholar
• Penn RB, Frielle T, McCullough JR, Comparison of R-, S-, and RS-albuterol interaction with human beta 1- and beta 2-adrenergic receptors. Clin Rev Allergy Immunol 1996;14:37-45
   PubMed Web of Science ®Google Scholar
• Page CP, Morley J. Contrasting properties of albuterol stereoisomers. J Allergy Clin Immunol 1999;104(2):S31-41
   Google Scholar
• Maier G, Rubino C, Hsu R, Population pharmacokinetics of (R)-albuterol and (S)-albuterol in pediatric patients aged 4 – 11 years with asthma. Pulm Pharmacol Ther 2007;20(5):534-42
   Google Scholar
• Gumbhir-Shah K, Kellerman DJ, DeGraw S, Pharmacokinetics and pharmacodynamics of cumulative single doses of inhaled salbutamol enantiomers in asthmatic subjects. Pulm Pharmacol Ther 1999;12(6):353-62
   PubMedGoogle Scholar
• Dhand R, Goode M, Reid R, Preferential pulmonary retention of (S)-albuterol after inhalation of racemic albuterol. Am J Respir Crit Care Med 1999;160:1136-41
   PubMed Web of Science ®Google Scholar
• Ward JK, Dow J, Dallow N, Enantiomeric disposition of inhaled, intravenous and oral racemic-salbutamol in man – no evidence of enantioselective lung metabolism. Br J Clin Pharmacol 2000;49(1):15-22
   PubMedGoogle Scholar
• Hoiting BH, Meurs H, Schuiling M, Modulation of agonist-induced phosphoinositide metabolism, Ca2+ signalling and contraction of airway smooth muscle by cyclic AMP-dependent mechanisms. Br J Pharmacol 1996;117:419-26
   PubMed Web of Science ®Google Scholar
• Mitra S, Ugur M, Ugur O, (S)-albuterol increases intracellular free calcium by muscarinic receptor activation and a phospholipase C-dependent mechanism in airway smooth muscle. Mol Pharmacol 1998;53:347-54
   PubMed Web of Science ®Google Scholar
• Delmotte P, Sanderson MJ. Effects of formoterol on contraction and Ca2+ signaling of mouse airway smooth muscle cells. Am J Respir Cell Mol Biol 2010;42(3):373-81
   PubMedGoogle Scholar
• Barnes PJ. Effect of beta-agonists on inflammatory cells. J Allergy Clin Immunol 1999;104(2):S10-17
   Google Scholar
• Volcheck GW, Kelkar P, Bartemes KR, Effects of (R)- and (S)-isomers of beta-adrenergic agonists on eosinophil response to interleukin-5. Clin Exp Allergy 2005;35(10):1341-6
   PubMedGoogle Scholar
• Leff AR, Herrnreiter A, Naclerio RM, Effect of enantiomeric forms of albuterol on stimulated secretion of granular protein from human eosinophils. Pulm Pharmacol Ther 1997;10(2):97-104
   PubMedGoogle Scholar
• Baramki D, Koester J, Anderson AJ, Borish L. Modulation of T-cell function by (R)- and (S)-isomers of albuterol: anti-inflammatory influences of (R)-isomers are negated in the presence of the (S)-isomer. J Allergy Clin Immunol 2002;109(3):449-54
   PubMedGoogle Scholar
• Ameredes BT, Calhoun WJ. Modulation of GM-CSF release by enantiomers of beta-agonists in human airway smooth muscle. J Allergy Clin Immunol 2005;116(1):65-72
   PubMedGoogle Scholar
• Chorley BN, Li Y, Fang S, (R)-albuterol elicits antiinflammatory effects in human airway epithelial cells via iNOS. Am J Respir Cell Mol Biol 2006;34(1):119-27
   PubMedGoogle Scholar
• Cho SH, Hartleroad JY, Oh CK. (S)-albuterol increases the production of histamine and IL-4 in mast cells. Int Arch Allergy Immunol 2001;124(4):478-84
   PubMedGoogle Scholar
• Agrawal DK, Ariyarathna K, Kelbe PW. (S)-Albuterol activates pro-constrictory and pro-inflammatory pathways in human bronchial smooth muscle cells. J Allergy Clin Immunol 2004;113(3):503-10
   PubMedGoogle Scholar
• Ibe BO, Abdallah MF, Raj JU. Mechanisms by which S-albuterol induces human bronchial smooth muscle cell proliferation. Int Arch Allergy Immunol 2008;146(4):321-33
   PubMedGoogle Scholar
• Matera MG, Calzetta L, Rogliani P, Evaluation of the effects of the R- and S-enantiomers of salbutamol on equine isolated bronchi. Pulm Pharmacol Ther 2011;24(2):221-6
   Google Scholar
• Templeton AG, Chapman ID, Chilvers ER, Effects of S-salbutamol on human isolated bronchus. Pulm Pharmacol Ther 1998;11(1):1-6
   PubMedGoogle Scholar
• Henderson WR Jr, Banerjee ER, Chi EY. Differential effects of (S)- and (R)-enantiomers of albuterol in a mouse asthma model. J Allergy Clin Immunol 2005;16:332-40
   Google Scholar
• Auais A, Wedde-Beer K, Piedimonte G. Anti-inflammatory effect of albuterol enantiomers during respiratory syncytial virus infection in rats. Pediatr Pulmonol 2005;40:228-34
   PubMedGoogle Scholar
• Keir S, Page C, Spina D. Bronchial hyperresponsiveness induced by chronic treatment with albuterol: role of sensory nerves. J Allergy Clin Immunol 2002;110(3):388-94
   PubMedGoogle Scholar
• Mazzoni L, Naef R, Chapman ID, Morley J. Hyperresponsiveness of the airways following exposure of guinea-pigs to racemic mixtures and distomers of beta 2-selective sympathomimetics. Pulm Pharmacol 1994;7:367-76
   PubMedGoogle Scholar
• Perrin-Fayolle M, Blum PS, Morley J, Differential responses of asthmatic airways to enantiomers of albuterol. Implications for clinical treatment of asthma. Clin Rev Allergy Immunol 1996;14:139-47
   PubMed Web of Science ®Google Scholar
• Cockcroft DW, Swystun VA. Effect of single doses of S-salbutamol, R-salbutamol, racemic salbutamol, and placebo on the airway response to methacholine. Thorax 1997;52:845-8
   PubMed Web of Science ®Google Scholar
• Ramsay CM, Cowan J, Flannery E, Bronchoprotective and bronchodilator effects of single doses of (S)-salbutamol, (R)-salbutamol and racemic salbutamol in patients with bronchial asthma. Eur J Clin Pharmacol 1999;55:353-9
   PubMed Web of Science ®Google Scholar
• Lotvall J, Palmqvist M, Arvidsson P, The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients. J Allergy Clin Immunol 2001;108(5):726-31
   PubMedGoogle Scholar
• Sjosward KN, Hmani M, Davidsson A, Single-isomer R-salbutamol is not superior to racemate regarding protection for bronchial hyperresponsiveness. Respir Med 2004;98:990-9
   PubMedGoogle Scholar
• Pleskow WW, Nelson HS, Schaefer K, Pairwise comparison of levalbuterol versus racemic albuterol in the treatment of moderate-to-severe asthma. Allergy Asthma Proc 2004;25:429-36
   PubMed Web of Science ®Google Scholar
• Nowak RM, Emerman CL, Schaefer K, Levalbuterol compared with racemic albuterol in the treatment of acute asthma: results of a pilot study. Am J Emerg Med 2004;22(1):29-36
   PubMedGoogle Scholar
• Nowak R, Emerman C, Hanrahan JP, A comparison of levalbuterol with racemic albuterol in the treatment of acute severe asthma exacerbations in adults. Am J Emerg Med 2006;24:259-67
   PubMed Web of Science ®Google Scholar
• Thompson M, Wise S, Rodenberg H. A preliminary comparison of levalbuterol and albuterol in prehospital care. J Emerg Med 2004;26(3):271-7
   PubMedGoogle Scholar
• Jantikar A, Brashier B, Maganji M, Comparison of bronchodilator responses of levosalbutamol and salbutamol given via a pressurized metered dose inhaler: a randomized, double blind, single-dose, crossover study. Respir Med 2007;101(4):845-9
   PubMedGoogle Scholar
• Hamilos DL, D'Urzo A, Levy RJ, Long-term safety study of levalbuterol administered via metered-dose inhaler in patients with asthma. Ann Allergy Asthma Immunol 2007;99:540-8
   PubMed Web of Science ®Google Scholar
• Tripp K, McVicar WK, Nair P, A cumulative dose study of levalbuterol and racemic albuterol administered by hydrofluoroalkane-134a metered-dose inhaler in asthmatic subjects. J Allergy Clin Immunol 2008;122(3):544-9
   PubMedGoogle Scholar
• Carl JC, Myers TR, Kirchner HL, Kercsmar CM. Comparison of racemic albuterol and levalbuterol for treatment of acute asthma. J Pediatr 2003;143(6):731-6
   PubMedGoogle Scholar
• Gawchik SM, Saccar CL, Noonan M, The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients. J Allergy Clin Immunol 1999;103(4):615-21
   PubMedGoogle Scholar
• Skoner DP, Greos LS, Kim KT, Evaluation of the safety and efficacy of levalbuterol in 2 – 5-year-old patients with asthma. Pediatr Pulmonol 2005;40:477-86
   PubMed Web of Science ®Google Scholar
• Milgrom H, Skoner DP, Bensch G, Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol. J Allergy Clin Immunol 2001;108(6):938-45
   PubMedGoogle Scholar
• Punj A, Prakash A, Bhasin A. Levosalbutamol vs racemic salbutamol in the treatment of acute exacerbation of asthma. Indian J Pediatr 2009;76:1131-5
   PubMedGoogle Scholar
• Hardasmalani MD, DeBari V, Bithoney WG, Gold N. Levalbuterol versus racemic albuterol in the treatment of acute exacerbation of asthma in children. Pediatr Emerg Care 2005;21(7):415-19
   PubMedGoogle Scholar
• Qureshi F, Zaritsky A, Welch C, Clinical efficacy of racemic albuterol versus levalbuterol for the treatment of acute pediatric asthma. Ann Emerg Med 2005;46(1):29-36
   PubMedGoogle Scholar
• Ralston ME, Euwema MS, Knecht KR, Comparison of levalbuterol and racemic albuterol combined with ipratropium bromide in acute pediatric asthma: a randomized controlled trial. J Emerg Med 2005;29(1):29-35
   PubMedGoogle Scholar
• Truitt T, Witko J, Halpern M. Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma. Chest 2003;123:128-35
   PubMed Web of Science ®Google Scholar
• Donohue JF, Parsey MV, Andrews C, Evaluation of the efficacy and safety of levalbuterol in subjects with COPD. COPD 2006;3:125-32
   PubMedGoogle Scholar
• Freiler JF, Arora R, Kelley TC, Randomized placebo controlled assessment of airway inflammation due to racemic albuterol and levalbuterol via exhaled nitric oxide testing. Int J Chron Obstruct Pulmon Dis 2006;1:461-6
   PubMedGoogle Scholar
• Sears MR. Adverse effects of beta-agonists. J Allergy Clin Immunol 2002;110(Suppl. 6):S322-8
   Google Scholar
• Schmekel B, Rydberg I, Norlander B, Stereoselective pharmacokinetics of S-salbutamol after administration of the racemate in healthy volunteers. Eur Respir J 1999;13:1230-5
   PubMed Web of Science ®Google Scholar
• Ernst P, Habbick B, Suissa S, Is the association between inhaled beta-agonist use and life-threatening asthma because of confounding by severity? Am Rev Respir Dis 1993;148:75-9
   PubMed Web of Science ®Google Scholar
• Suissa S, Ernst P, Benayoun S, Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000;343:332-6
   PubMed Web of Science ®Google Scholar